雷珠单抗和康柏西普治疗湿性年龄相关性黄斑变性的临床效果分析

Clinical Efficacy Analysis of Ranibizumab and Conbercept in the Treatment of Wet Age-related Macular Degeneration

目的旨在分析临床上湿性年龄相关性黄斑变性患者实施治疗期间选用雷珠单抗、康柏西普的具体效果。方法在本院接收的湿性年龄相关性黄斑变性患者中遴选80例,时间为2021年1月-2024年7月。通过抽签法实施分组,将患者分成观察组、对照组,各纳入40例。对照组治疗期间提供雷珠单抗,观察组则提供康柏西普。分析患者的裸眼视力数据、黄斑中心凹视网膜厚度数据、并发症数据。结果两组患者未经治疗前的裸眼视力数据未呈现统计学差异(P>0.05),观察组患者关于治疗1周后、治疗1月后的裸眼视力数据则优于对照组(P<0.05);两组患者未经治疗前的黄斑中心凹视网膜厚度数据未呈现统计学差异(P>0.05),观察组患者关于治疗1周后、治疗1月后的黄斑中心凹视网膜厚度数据则低于对照组(P<0.05)。两组患者关于眼压增高、眼球胀痛、结膜充血等总发生率未呈现统计学差异(P>0.05)。结论临床上治疗湿性年龄相关性黄斑变性患者期间,选用康柏西普的近期疗效会优于雷珠单抗,其能够降低黄斑中心凹视网膜厚度,促使患者的裸眼视力获得改善,且并发症较少,建议参考。

Objective To analyze the specific effects of using ranibizumab and conbercept during the treatment of patients with wet agerelated macular degeneration in clinical practice.Method 80 patients with wet age-related macular degeneration admitted to our hospital were selected from January 2021 to July 2024.The patients were divided into an observation group and a control group,with 40 cases in each group,using the lottery method for grouping.During the treatment period,the control group was provided with ranibizumab,while the observation group was provided with conbercept.Analyze the patient's uncorrected visual acuity data,macular fovea retinal thickness data,and complication data.Result There was no statistically significant difference in the uncorrected visual acuity data between the two groups of patients before treatment(P>0.05).The observation group had better uncorrected visual acuity data than the control group after 1 week and 1 month of treatment(P<0.05);There was no statistically significant difference in the retinal thickness data of the macular fovea between the two groups of patients before treatment(P>0.05).The observation group had lower retinal thickness data of the macular fovea after 1 week and 1 month of treatment than the control group(P<0.05);There was no statistically significant difference between the two groups of patients in terms of the overall incidence of increased intraocular pressure,eye swelling and pain,conjunctival congestion(P>0.05).Conclusion During the clinical treatment of patients with wet age-related macular degeneration,the short-term efficacy of using Conbercept is superior to that of ranibizumab.It can reduce the thickness of the foveal retina,improve the naked eye vision of patients,and there are fewer complications.It is recommended to refer to it.